Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

NCT02507284 is registered in ClinicalTrials.gov with Azevan Pharmaceuticals as lead sponsor.

NCT NCT02507284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02507284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Lead sponsor
Azevan Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2016
Completion date
December 21, 2018
Enrollment
106 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

huntington's disease, irritable mood